Press |

Berichten in: 'Nierkanker'

SABR en pembro goede resultaten bij oligometastatische RCC, RAPPORT Trial

3 januari, 2022

The combination of stereotactic ablative body radiotherapy (SABR) and a short-course of pembrolizumab is well tolerated and provides excellent local control of oligometastatic renal-cell carcinoma (RCC), according to results of the RAPPORT trial. Read: Stereotactic Radiotherapy With Pembrolizumab Promising for Oligometastatic Kidney Cancer in ‘European Urology’ Meer op DUOS...

Category: Featured, News, Nierkanker

Nieuwe EAU richtlijn Renal Cell Carcinoma

4 december, 2021

Updated guidelines on the management of renal cell carcinoma (RCC) were published in October 2021 by the European Association of Urology (EAU) in European Urology. If the results of contrast-enhanced computed tomography (CT) are indeterminate, use non-ionizing modalities, including magnetic resonance imaging (MRI) and contrast-enhanced ultrasound, for further characterization of...

Category: Featured, News, Nierkanker

Nivolumab-Cabozantinib combinatie boosts overleving in nierkanker

4 december, 2021

Previously untreated patients with advanced renal-cell carcinoma live twice as long without disease progression when given a combination of nivolumab and cabozantinib instead of sunitinib, according to results from the CheckMate 9ER study. Bristol Myers Squibb helped pay for the phase-3, randomized, open-label trial of 651 patients, where the...

Category: Featured, News, Nierkanker

Lenvatinib-Pembrolizumab combinatie veelbelovend in gemetastaseerde nierkanker

4 december, 2021

The combination of the multikinase inhibitor lenvatinib and the anti-PD-1 antibody pembrolizumab has “encouraging” antitumor activity and a manageable side effect profile and might be an option following immune-checkpoint inhibitor (ICI) therapy in patients with metastatic renal-cell carcinoma (RCC), researchers report. Despite advances in the first-line treatment of metastatic...

Category: Featured, News, Nierkanker

FDA keurt adjuvant pembrolizumab goed bij RCC

4 december, 2021

Pembrolizumab (Keytruda) has been granted approval from the US Food and Drug Administration for use as an adjuvant treatment following surgery in certain patients with renal cell carcinoma (RCC), making it the first immunotherapy to have this indication. Specifically, the approval is for the adjuvant treatment of patients with RCC...

Category: Featured, News, Nierkanker

Cabozantinib een optie voor nierkanker met hersenmetastases

3 november, 2021

Cabozantinib showed intracranial activity and an acceptable safety profile in a retrospective study (published in JAMA) of patients with renal cell carcinoma (RCC) with brain metastases, researchers say. Because the data are retrospective, they believe surgery +/- radiation should be the primary modality for brain mets. ‘If, overall, the...

Category: Featured, News, Nierkanker

© 2022, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in